261 related articles for article (PubMed ID: 27666138)
1. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy.
Peng J; Wei Y; Zhou F; Dai J; Zhong Y; Xie C; Qin Y; Gong J; Xiong B; Zhou Y
Cancer Med; 2016 Oct; 5(10):2773-2780. PubMed ID: 27666138
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.
Wang X; Shen Y; Zhu H; Zhao Y; Li Z; Qiu M; Li Q; Gou H; Yang Y; Cao D; Liu J; Yi C; Liao Z; Luo D; Bi F; Xu F
Gastric Cancer; 2016 Jan; 19(1):245-54. PubMed ID: 25609451
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?
Kilic L; Ordu C; Ekenel M; Yildiz I; Keskin S; Sen F; Gural Z; Asoglu O; Kizir A; Aykan F
Med Oncol; 2013; 30(3):660. PubMed ID: 23877872
[TBL] [Abstract][Full Text] [Related]
5. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
[TBL] [Abstract][Full Text] [Related]
6. Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate.
Feng YR; Jin J; Ren H; Wang X; Wang SL; Wang WH; Song YW; Liu YP; Tang Y; Li N; Liu XF; Fang H; Yu ZH; Li YX
BMC Cancer; 2017 Mar; 17(1):182. PubMed ID: 28279170
[TBL] [Abstract][Full Text] [Related]
7. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemoradiation in gastric cancer: long-term outcomes and prognostic factors from a single institution.
Bruixola G; Segura Á; Díaz-Beveridge R; Caballero J; Bennis MH; Palomar L; Giménez A; Mingol F; García-Mora C; Aparicio J
Tumori; 2015; 101(5):517-23. PubMed ID: 26045120
[TBL] [Abstract][Full Text] [Related]
9. Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection--do N3 patients benefit from additional radiation?
Fan M; Li G; Shen L; Zhang H; Liang L; Zhang Z
Br J Radiol; 2016; 89(1059):20150758. PubMed ID: 26728420
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemoradiation versus chemotherapy for stage III gastric cancer after surgery with curative intent.
Turanli S; Atalay C; Berberoglu U; Gulben K
J Cancer Res Ther; 2015; 11(2):369-74. PubMed ID: 26148602
[TBL] [Abstract][Full Text] [Related]
13. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
15. Age as a modifier of the effects of chemoradiotherapy with infusional 5-fluorouracil after D2 dissection in gastric cancer.
Wu HC; Lin WL; Lin CL; Lin CY; Chen SW; Chen YX; Chen CH; Lee SW; Chen SH; Tsao CJ; Huang WT; Guo HR
Aging (Albany NY); 2021 Jul; 13(13):17337-17348. PubMed ID: 34226296
[TBL] [Abstract][Full Text] [Related]
16. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
[TBL] [Abstract][Full Text] [Related]
17. The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis.
Wang ZX; Yang XL; He MM; Wang F; Zhang DS; Li YH; Zhou ZW; Zhan YQ; Xu RH
Medicine (Baltimore); 2016 Apr; 95(16):e3214. PubMed ID: 27100411
[TBL] [Abstract][Full Text] [Related]
18. ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER?
Andreollo NA; Drizlionoks E; Tercioti-Junior V; Coelho-Neto JS; Ferrer JAP; Carvalheira JBC; Lopes LR
Arq Bras Cir Dig; 2019; 32(4):e1464. PubMed ID: 31859917
[TBL] [Abstract][Full Text] [Related]
19. Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy.
Kucukoner M; Arpaci E; Isikdogan A; Bilici M; Uncu D; Cetin B; Dane F; Inanc M; Ekinci AS; Inal A; Cayir K; Yetisyigit T; Ozdemir N; Kaplan MA; Aksoy S; Alkıs N; Tekin SB; Eroglu C; Turhal S; Buyukberber S
Neoplasma; 2013; 60(1):19-25. PubMed ID: 23067212
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]